Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samuraciclib in Localized Basal Pancreatic Cancer
NCT07645651Phase 1Recruiting
- Sponsor
- University of Washington
- Start
- Dec 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of samuraciclib in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Washington. Primary endpoint: Change in Ribonucleic Acid Polymerase II Serine Levels at 72 hours. Planned start Dec 2026; status: recruiting.
02
Drugs
samuraciclib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07645651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645651.